WHO Issues Concern Over Severe Lack of Obesity Jabs

Fewer than one in 10 people who could benefit from obesity jabs such as Wegovy can access them, warns the World Health Organization as it publishes its initial advice on the drugs.

Considering over a billion individuals worldwide now classified as obese, it is calling for broader and more equitable access to this class of drugs.

Per estimates, over two billion will be living with obesity by 2030 without intervention.

"Our latest guidelines recognises that excess weight is a long-term condition that can be managed with comprehensive and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are major barriers to broad access to the treatments that can aid individuals in losing significant weight, notes the body.

GLP-1 Therapy Shortage

Even in the present most optimistic case, the supply of GLP-1 therapies would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the health organization.

The advice calls on governments and firms to increase availability, through strategies like patent sharing.

Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is due to expire in a number of countries in 2026.

How Weight-Loss Injections Function

GLP-1 drugs imitate a body's own hormone to delay gastric emptying, curb appetite and increase the sense of being full so people consume fewer calories.

Individuals commonly start to lose weight after several weeks of commencing the weekly injections.

Evidence indicates patients may put most of the weight back on a year later of halting the drug, as their usual appetite resume.

To be above a healthy weight raises your chance for contracting diseases, such as type 2 diabetes, heart disease, brain attack, and specific malignancies.

Obesity concerns individuals in all nations and was responsible for millions of deaths worldwide in 2024, according to the WHO.